Simplifying the Prior Authorization Process in IBD

PROGRAM DESCRIPTION Almost 60% of GI providers have had a patient’s biologic treatment switched due to insurance rules. Prior authorization barriers often restrict patients' access to therapy. Don't let this ...

PROGRAM DESCRIPTION
Almost 60% of GI providers have had a patient’s biologic treatment switched due to insurance rules. Prior authorization barriers often restrict patients' access to therapy. Don't let this happen to your patients.

EDUCATIONAL OBJECTIVES
Upon completion of this educational activity, participants should be able to:Describe real-world ways to reduce time spent on prior authorizations for biologic therapies used for patients with moderate to severe IBD.Explain how to establish a protocol to consistently document data required for prior authorizations and communicate it more effectively to payers.List the different ways practices can use to complete PAs, as well as the pros and cons of methods including NCPDP ePA transactions, payer portals and secure emails.List tools and resources that can improve provider/payer relationships and simplify the prior authorization and appeals process for GI practices.Identify situations where a biologic drug should be considered early and discuss supporting evidence for appeals letters.

---

Write the first review

Resource tags